Patents by Inventor Barrett Harvey

Barrett Harvey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150337284
    Abstract: Variants of factor IX with increased membrane binding affinity, and the use of such variants for treating factor IX deficiency, are described.
    Type: Application
    Filed: September 30, 2013
    Publication date: November 26, 2015
    Inventors: Gary L. Nelsestuen, Stephen Barrett Harvey
  • Patent number: 8632771
    Abstract: Modifications of vitamin K-dependent polypeptides that lead to enhanced protein function on a weight or molar basis and/or increase of protein lifetime in the circulation are described. Both objectives are important for using vitamin K-dependent polypeptides for pro- and anti-coagulation therapies, as well as for other uses in the circulation.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: January 21, 2014
    Assignees: Regents of the University of Minnesota, The United States of America as represented by Department of Veterens Affairs
    Inventors: Gary L. Nelsestuen, Ronald Bach, Matthew Stone, Stephen Barrett Harvey
  • Publication number: 20070099267
    Abstract: The invention overcomes the deficiencies of the prior art by providing a rapid approach for isolating binding proteins capable of binding small molecules and peptides. In the technique, libraries of candidate binding proteins, such as antibody sequences, are expressed in the periplasm of gram negative bacteria and mixed with a labeled ligand. In clones expressing recombinant polypeptides with affinity for the ligand, the concentration of the labeled ligand bound to the binding protein is increased and allows the cells to be isolated from the rest of the library. Where fluorescent labeling of the target ligand is used, cells may be isolated by fluorescence activated cell sorting (FACS). The approach is more rapid than prior art methods and avoids problems associated with the outer surface-expression of ligand fusion proteins employed with phage display.
    Type: Application
    Filed: August 22, 2006
    Publication date: May 3, 2007
    Inventors: Barrett Harvey, George Georgiou, Brent Iverson
  • Publication number: 20050267294
    Abstract: The invention overcomes the deficiencies of the prior art by providing antibody compositions having improved affinities for Bacillus anthracis antigens. The compositions have important thereapeutic and diagnostic applications, including treatment or detection of infection by Bacillus anthracis.
    Type: Application
    Filed: July 12, 2005
    Publication date: December 1, 2005
    Inventors: Barrett Harvey, George Georgiou, Brent Iverson
  • Publication number: 20050260736
    Abstract: The invention overcomes the deficiencies of the prior art by providing a rapid approach for isolating polypeptides capable of anchoring heterologous polypeptides to a bacterial inner membrane. In the technique, libraries of candidate anchor polypeptides are expressed as fusions with a heterologous polypeptide that is capable of being detected when bound to the inner membrane. In bacteria expressing a functional anchor sequence, the heterologous polypeptide becomes bound to outer face of the inner membrane. Bacteria with the functional anchor sequence can be identified by removing the outer membrane to remove non-anchored heterologous polypeptide followed by detection of anchored heterologous polypeptide. Such bacteria may be detected in numerous ways, including use of direct fluorescence or secondary antibodies that are fluorescently labeled, allowing use of efficient techniques such as fluorescence activated cell sorting (FACS).
    Type: Application
    Filed: March 18, 2005
    Publication date: November 24, 2005
    Inventors: George Georgiou, Ki Jun Jeong, Barrett Harvey, Brent Iverson
  • Publication number: 20050106647
    Abstract: The invention overcomes the deficiencies of the prior art by providing antibody compositions having improved affinities for Bacillus anthracis antigens. The compositions have important thereapeutic and diagnostic applications, including treatment or detection of infection by Bacillus anthracis.
    Type: Application
    Filed: July 15, 2003
    Publication date: May 19, 2005
    Inventors: Barrett Harvey, George Georgiou, Brent Iverson